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Abstract: Metabolic-associated fatty liver disease (MAFLD) is the most important cause of liver
disease worldwide. It is characterized by the accumulation of fat in the liver and is closely associated
with abdominal obesity. In addition, oxidative stress and inflammation are significant features
involved in MAFLD. Recently, our group demonstrated that lupin protein hydrolysates (LPHs) had
lipid lowering, antioxidant, and anti-inflammatory effects. Sixty male mice fed with a Western diet
were intragastrically treated with LPHs (or vehicle) for 12 weeks. Liver and adipose tissue lipid
accumulation and hepatic inflammatory and oxidant status were evaluated. A significant decrease in
steatosis was observed in LPHs-treated mice, which presented a decreased gene expression of CD36
and LDL-R, crucial markers in MAFLD. In addition, LPHs increased the hepatic total antioxidant
capacity and reduced the hepatic inflammatory status. Moreover, LPHs-treated mice showed a
significant reduction in abdominal adiposity. This is the first study to show that the supplementation
with LPHs markedly ameliorates the generation of the steatotic liver caused by the intake of a Western
diet and reduces abdominal obesity in ApoE−/− mice. Future clinical trials should shed light on the
effects of LPHs on MAFLD.
Keywords: lupin; bioactive peptides; NAFLD; oxidative stress; inflammation; adipose tissue; steato-
sis; cholesterol; LDL
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1. Introduction
Metabolic-associated fatty liver disease (MAFLD) is the principal cause of chronic
liver disease worldwide, with an estimated global prevalence of 25–30% [1,2]. MAFLD is
associated with metabolic risk factors such as insulin resistance, hyperlipidemia and central
obesity [3]. In fact, MAFLD prevalence can range 67–91% in obese subjects, depending on
the BMI and waist circumference [4]. MAFLD presents a wide spectrum of clinical phe-
notypes that range from simple steatosis (SS) to non-alcoholic steatohepatitis (NASH) [5].
SS is characterized by the presence of more than 5% lipids in hepatocytes while NASH is
characterized by advanced steatosis, ballooning, and lobular inflammation [6]. Frequently,
NASH may progress to fibrosis, hepatic cirrhosis, and finally to hepatocellular carcinoma,
which can end up with the need for a liver transplant [5].
Regarding the pathophysiology of MAFLD, the theory of “multiple hits model” has
replaced the earlier “two hits hypothesis” in which obesity and insulin resistance gen-
erate an hepatic accumulation of lipids (first hit) that activate oxidative stress and an
inflammatory cascade and fibrogenesis (second hit) [7]. The multiple hits model maintains
the formers hits (oxidative stress and inflammation), but adds a more complex vision of
human MAFLD, including genetic and dietary factors, interactions with other organs, and
metabolic dysfunction [8]. Thus, several studies have demonstrated a dysregulation of
triglycerides [9] and cholesterol [10] metabolism in MAFLD which is associated with the
severity of the disease. This dysregulation affects receptors, hormones, and transcription
factors, causing lipid accumulation in the liver [11]. In fact, an increase in the expres-
sion of hepatic enzymes involved in triglycerides synthesis, such as fatty acid synthase
(FASN) [12], and the cluster of differentiation (CD) 36 [13], which promote the long-chain
fatty acids uptaking in the liver, has been shown in MAFLD patients. In contrast, the low
density lipoprotein receptor (LDL-R) expression, implicated in the cholesterol metabolism,
is reduced [10].
Furthermore, MAFLD is strongly associated with the endocrine cross-talk between
liver and adipose tissue [14]. In this regard, adiponectin receptor 2 (AdipoR2), the liver
receptor of adiponectin, a protein secreted from adipose tissue that has been shown to pos-
sess anti-inflammatory, anti-lipidemics, and anti-diabetic effects [15], has been suggested
to play an important role in the pathogenesis of MAFLD [15].
The diet have also been suggested to contribute to MAFLD development [16]. In this
regard, diets rich in saturated fats and added sugar contribute to the hepatic accumulation
of fats, to increase the oxidative stress and the inflammatory response [8,17,18]. Moreover,
several studies have demonstrated that healthy changes in dietary habits can promote a
clinically meaningful regression of disease status [19]. For this reason, life-style interven-
tions based on nutritional changes is considered the first line therapy in preventing or
ameliorating MAFLD [20]. In this way, plant peptide such as those from soy have been
shown not only to lower the MAFLD status in animals [21] and humans [18] but also to be
able to decrease the main obesity risk factors [21].
Apolipoprotein E (ApoE) plays a pivotal role in fat metabolism and lipid homeostasis
by binding to LDL-R and ApoE-specific remnant receptors [22]. Previous studies have
demonstrated that ApoE absence predisposes to hypercholesterolemia and atherosclero-
sis [23,24]. Besides, ApoE Knockout mice (ApoE−/−) have a higher inflammatory and
oxidative stress status compared to wild type mice [25]. Moreover, a seven weeks treat-
ment of Western Diet (WD) has been shown to be enough to induce MAFLD in ApoE−/−
mice [25,26] unlike other models that need longer induction time. Therefore, the use of
WD in ApoE mice reduces time and cost. In addition, previous reports have shown that
WD, besides increase hyperlipidemia, exacerbates inflammation and oxidative stress pro-
moting metabolic syndrome and MAFLD generation with great similarity to the human
disease [26].
Our group has recently demonstrated that lupin protein hydrolysates (LPHs), obtained
from hydrolysis of Lupinus angustifolius, exert blood lipid-lowering, antioxidant, and anti-
inflammatory effects [27,28]. Given that growing evidence emphasizes that changes in
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the diet cause correction of obesity and the subsequent remission of steatosis [19,29], we
hypothesize that LPHs treatment could reduce the risk in developing MAFLD. Therefore,
the aim of this study was to evaluate the effect of LPHs on abdominal obesity and liver
status of ApoE−/− mice fed a WD.
2. Materials and Methods
2.1. LPHs Preparation
LPHs were obtained at the Instituto de la Grasa of Seville (Consejo Superior de
Investigaciones Científicas, Seville, Spain) as described previously [27].
2.2. Animals, Experimental Protocol and Dosage Information
The experimental design is shown in Figure 1. Sixty 4-week-old male ApoE−/− mice
were housed in the animal facility of Instituto de Biomedicina de Sevilla (IBiS) under
standard conditions (12/12 light/dark cycles, temperature 22 ± 2 ◦C and humidity <55%)
with free access to water and WD (Test Diet 58v8, 45% Energy from Fat). The composi-
tion of WD is shown in supporting information Table S1. After two weeks, mice were
randomized into two groups and intragastrically treated five days/week with vehicle (WD
group) or LPHs (WD+LPHs group) for 12 weeks. LPHs were administered at 100 mg/Kg
dissolved in 0.9% saline and 0.25% carboxymethyl cellulose (CMC) (Sigma Aldrich, St.
Louis, MO, USA). WD mice received the same treatment without LPHs. LPHs dose was
selected based on previous internal tests. The human equivalent dose was 8.12 mg/Kg
calculated, according to [30]. Daily food intake and individual body weight were measured
weekly and recorded. At the experiment endpoint (18 weeks), fasted animals were eutha-
nized with an intraperitoneal injection of sodium thiopental (50 mg/Kg, B. Braun Medical
SA, Barcelona, Spain) and the blood was removed by perfusion with phosphate-buffered
saline (PBS) for 5 min through a Thermo FH100 peristaltic pump (Thermo Fisher Scientific,
Vantaa, Finland). Abdominal white adipose tissue (WAT) and liver were subsequently
collected, weighed and stored until used. The experimental protocol was performed under
the Spanish legislation and the EU Directive 2010/63/EU for animal experiments and
was approved by the Virgen Macarena and Virgen del Rocío University Hospitals ethical
committee (reference 21/06/2016/105). Initial ApoE−/− mice to generate the colony were
kindly gifted by Dr. Antonio Ordoñez and Dr. Raquel del Toro (IBiS).
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Figure 1. Experimental design and timeline. Schematic diagram of the experimental design of the study. WD, Western diet;
LPHs, lupin rotein hydrolysates.
2.3. Liver Lipids Quantification
Liver was homogenized in chloroform:isopropanol:Nonidet P-40 (Sigma Aldrich)
(7:11:0.1 v/v/v). Samples were centrifuged at 10,000× g for 10 min at 4 ◦C and the su-
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pernatant was collected and dried in a Jouan RC1022 evaporator (Thermo Fisher Sci-
entific). The pellet obtained was dissolved in saline 1% Nonidet P-40. Hepatic total
cholesterol (hTC) and hepatic triglycerides (hTG) levels were measured through a chemilu-
minescence immunoassay using the COBAS E 601® modular analyser (Roche Diagnostics,
Basel, Switzerland).
2.4. Histological Analysis
Frozen liver samples were sectioned at 10 µm and postfixed in 40% formaldehyde.
Slides were then stained with Oil Red O (Sigma Aldrich) for 10 min, counterstained with
Harris’s hematoxylin (PanReac AppliChem, Chicago, IL, USA) containing 4% acetic acid
for 2 min, and finally cover-mounted for observation. Paraformaldehyde-fixed liver and
WAT samples were routinely dehydrated, paraffin-embedded, and sectioned at 2–4 µm.
Slides were then stained with hematoxylin-eosin (PanReac AppliChem, Barcelona, Spain)
and cover-mounted for observation. Photomicrographs were obtained using an Olympus
photomicroscope (Vanox AHBT3, Olympus, Tokyo, Japan) and Nikon (DS-Fi310, Nikon,
Tokyo, Japan) digital camera. Adipocyte morphology (area and size) and hepatic steatosis
degree (lipid-droplet total area, number per cell, and average area) were estimated using
the NIH ImageJ v1.52p free software package (NIH, Bethesda, MD, USA). Data were
collected from an average of 200 cells, two hematoxylin-eosin-stained sections per mouse.
Histopathological changes were analysed blindly by two independent experimenters.
2.5. Antioxidant Capacity
The ferric reducing antioxidant power (FRAP) assay was measured in liver ho-
mogenate according to Escudero-López et al. [31]. 280 µL of FRAP reagent were mixed
with 20 µL sample. After 30 min of incubation at 37 ◦C, the absorbance (595 nm) was
read with a Synergy™ HT-multimode microplate reader (Biotek Instruments, Winooski,
VT, USA). The results were obtained by data extrapolation with a calibration curve
using 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox, Sigma Aldrich).
Lipid peroxidation was measured through the quantification of malondialdehyde (MDA)
and 4-hydroxynonenal (4-HNE). 40 µL of the sample was mixed with 130 µL methanol:
acetonitrile (1:3 v/v) solution, that contained the chromogen N-methyl-2-phenylindole.
Then, 30 µL methanesulfonic acid were added, incubated for 15 min at 60 ◦C and incubated
for 5 min on ice to stop the reaction. Moreover, the activity of the antioxidant enzymes CAT,
GPx (Cayman Chemical, Ann Arbor, MI, USA), SOD (Arbor Assays, Ann Arbor, MI USA)
and GR (Biovision, Milpitas, CA, USA) were measured in liver homogenate according to
the manufacturer’s indications. The absorbances were measured with a CLARIOstar Plus
microplate reader (BMG Labtech, Ortenberg, Germany). Liver homogenate was carried
out as follow. 100 mg frozen liver were homogenated in 4 mL of PBS containing protease
inhibitor cocktail (Sigma Aldrich) according to the manufacturer’s instructions using the
TissueRuptor II (Qiagen, Hilden, Germany). Samples were centrifuged at 12,000× g for
15 min at 4 ◦C and the supernatant was collected and frozen until use. Protein content
was measured according to Lowry protein assay by using the DC (detergent compatible)
protein assay (Bio-Rad, Hercules, CA, USA).
2.6. RNA Isolation and RT-qPCR
Livers were homogenized in TriSure Isolation Reagent (Bioline, Luckenwalde, Ger-
many) using the TissueRuptor II. RNA isolation was carried out according to the manu-
facturer’s instructions. cDNA was obtained by using the Transcriptor First Strand cDNA
Synthesis Kit (Roche). Quantitative PCR was performed with 80 ng cDNA/well in the
Lightcycler 480 thermocycler with the LightCycler 480 SYBR Green I Master kit (all from
Roche). Hypoxanthine phosphoribosyltransferase (hprt) was used as the housekeeping
gene and the relative expression levels were calculated using the 2−∆∆Ct method. Primers
used: AdipoR2, forward (Fwd) 5′-ATTTGGAGCCCAGCTTAGAGA-3′, reverse (Rev) 5′-
GCCTTCCCACACCTTACA-3′ (NM_197985), annealing temperature (Ta) = 54 ◦C; CD36,
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Fwd 5′-ATTCATTTGTTCAAGTTGTGC-3′, Rev 5′-AAAAGGTGGAAAGGAGGCTGC-3′
(NM_001159558), Ta = 52 ◦C; Fasn, Fwd 5′-AGAGATCCCGAGACGCTTCTG-3′, Rev 5′-
GCCTGGTAGGCATTCTGTAGT-3′ (NM_007988), Ta = 56 ◦C; Ldl-r, Fwd
5′-TCAGACGAACAAGGCTGTCC-3′, Rev 5′-CCATCTAGGCAATCTCGGTCTC-3′
(NM_010700), Ta = 61 ◦C; Sr-a, Fwd 5′-GGCTGGAGGGAAGTTGTCAATAC-3′, Rev
5′-TCTGCTGCATCCCACTGGTGA-3′ (NM_025291), Ta = 54 ◦C; Hprt, Fwd
5′-TGTTGGATATGCCCTTGACTA-3′, Rev 5′-TGCGCTCATCTTAGGCT-3′ (NM_013556),
Ta = 52.61 ◦C.
2.7. Statistical Analysis
The statistical analysis was performed using SPSS® statistic software v25 (IBM Cor-
poration, Armonk, NY, USA). Data were expressed as the mean and standard error of
the mean (SEM). Data did not follow a normal distribution so the differences between
the two experimental groups were evaluated through the unpaired and non-parametric
Mann-Whitney U test. Correlations were analysed by the non-parametric Spearman’s
correlation. Values of p ≤ 0.05 were considered statistically significant.
3. Results
3.1. LPHs Treatment Does Not Change Body Weight and Calorie Intake
As shown in Supporting Information Figure S1, no differences were observed either in
the baseline weights (BBW) or in the final body weight (FBW) in WD+LPHs-treated mice
compared to WD group. Furthermore, no changes in the body weight gain (BWG) and the
daily food intake (DFI) were observed between groups.
3.2. LPHs Ingestion Reduces Abdominal WAT Size
After 12 weeks of LPHs-treatment, a significant reduction in the abdominal WAT was
observed in comparison with the WD group (Figure 2A,B). Also, the histological analysis
of WAT sections showed that the number of adipocytes was significantly higher in the
WD group than WD+LPHs-treated mice (Figure 2C–E). A lower frequency of very large
adipocytes (>80 µm) was observed in WD+LPHs-treated mice in comparison with the
WD group (Figure 2F). In addition, WD+LPHs group showed a significant decrease in
adipose hypertrophy, by the reduction in area (Figure 2G), diameter (Figure 2H), and
volume (Figure 2I) of adipocytes. In fact, WD+LPHs mice showed a similar frequency of
large adipocytes and mean area, diameter and volume per adipocyte (Figure 2F–I) to the
standard diet (SD) group.
3.3. LPHs Decrease the Hepatic Steatosis
hTC and hTG concentrations were significantly reduced in WD+LPHs-treated mice in
comparison with the WD group without affecting liver/body weight ratio (Figure 3A–C)
To confirm the reduction of LPHs-induced steatosis, oil red staining was performed in
the liver. LPHs-treated mice showed a significant reduction of hepatic lipid accumulation
compared to the WD group (Figure 3D–J). Interestingly, the lipid accumulation observed in
the WD+LPHs group was similar to the fat concentration present in the liver of SD-fed mice.
Fat area (Figure 3G), fat droplets/cells (Figure 3H), and average fat droplets area (µm2)
(Figure 3I) were significantly reduced in LPHs-treated mice in comparison to WD group.
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3.4. LPHs Modulate Hepatic Lipid Metabolism-Related Genes
To evaluate whether LPHs could be affecting the expression of key genes involved
in the hepatic lipid metabolism, RT-qPCRs were performed (Figure 4). The CD36 gene
expression was significantly reduced in LPHs-treated mice in comparison to the WD
group whereas no differences were observed in the SR-A gene expression. Moreover, a
reduction in the LDL-R gene expression in the WD+LPHs group compared to WD group
was observed. In addition, LPHs treatment significantly increased the hepatic mRNA
relative expression of AdipoR2 and a trend towards a reduction was observed in mRNA
of FASN. Interestingly, a significantly strong positive correlation between hTG-CD36 and
hTC-LDL-R was shown (Table 1).
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tors (CD36, SR-A), adiponectin receptor II (adipoR2), fatty acid synthase (FASN), and low density
lipoprotein receptor (LDL-R) in the liver of mice after 12 week-treatment with LPHs. Data are shown
as the mean of 2−∆∆Ct and standard error of the mean of each group (n=10). * p ≤ 0.05, with respect
to the WD group. CD36, cluster of differentiation 36; SR-A, class A macrophage scavenger receptor;
WD, western diet group.
Table 1. Nonparametric correlations.
Spearman’s Correlations Parameters r p-Value
Lipid markers
CD36 and hTG 0.750 * 0.020
LDL-R and hTC 0.821 * 0.034
hTG and hTC 0.950 *** 0.000
FRAP and hTG −0.600 0.088
Antioxidant and anti-inflammatory FRAP and IL10/TNF ratio 0.762 * 0.028
Antioxidant activities
FRAP and GR activity 0.573 0.066
FRAP and GPx activity 0.641 * 0.025
FRAP and SOD activity 0.478 0.166
FRAP and [MDA + 4-HNE] −0.786 * 0.027
Non-parametric Spearman’s correlations between lipid, antioxidant, and inflammatory parameters in WD+LPHs
group (n = 10). * p ≤ 0.05, *** p ≤ 0.001. 4-HNE, 4-hydroxy-2-nonenal; CD36, cluster of differentiation 36; FRAP,
ferring reduction antioxidant power; GPx, glutathione peroxidase; GR, glutathione reductase; hTC, hepatic total
cholesterol; hTG, hepatic triglyceride; LDL-R, low density lipoprotein receptor; MDA, malondialdehyde.
3.5. LPHs Increase the Hepatic Antioxidant Capacity
A significant increase of the hepatic FRAP was detected in the WD+LPHs group in
respect to the WD group (Figure 5A). Furthermore, a trend towards a decrease in the lipid
peroxidation products (MDA+4-HNE) was observed in LPHs-treated mice (Figure 5B). In
fact, a significant negative correlation between hepatic FRAP and lipid peroxidation was
detected in the LPHs-treatment group. (Table 1). A significant enhancement in the SOD,
GPx and GR activities as well as a trend towards an increase in CAT activity were recorded
in the LPHs-treated mice liver (Figure 5C) Accordingly, GPx and GR activities showed a
strong positive correlation with FRAP (Table 1).
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4. Discussion
This study describes the beneficial effects of a 12 week-treatment of LPHs on WD-
induced abdominal adiposity and MAFLD in ApoE−/− mice. LPHs reduced WAT size, hep-
atic lipid accumulation and liver oxidative stress and promoted a hepatic anti-inflammatory
environment, critical components for the triggering and development of MAFLD. The
effects of LPHs were related to neither the diet intake nor the BWG of mice that remained
unchanged in the two experimental groups (WD and WD + LPHs).
MAFLD is the most common liver disorder worldwide [2,5]. Its incidence has been
increasing over the last years, now affecting up to 25% of the general population [32]. Due
Antioxidants 2021, 10, 1222 10 of 15
to the strong socioeconomic and sanitary global impact caused by MAFLD [33], the interest
in potential treatments has increased in the last decade [34]. ApoE−/− mice is the principal
genetic murine model of MAFLD [34]. In this regard, recent studies have shown steatosis,
inflammation, and hepatic collagen accumulation in ApoE−/− mice fed with high fat diet
(HFD) [26].
The principal risk factor of MAFLD is the presence of metabolic syndrome of which
the abdominal obesity is the primary component [35]. In fact, 80–90% of obese adults
present MAFLD [36]. In this study, we observed that LPHs-treated mice not only presented
a smaller size of abdominal WAT, but also a reduction of the adipocyte hypertrophy. As
far as we know, this is the first study to report the beneficial effect of LPHs on abdominal
obesity.
Hepatic steatosis, consisting in the accumulation of more than 5% lipids in hepatocytes,
is the initial stage of MAFLD [37]. Our results showed that LPHs treatment reduced hTC
and hTG in WD-fed ApoE−/− mice. Furthermore, the histological liver analysis confirmed
a LPHs-induced reduction of hepatic steatosis. Previous studies have demonstrated that
both whole protein and lupin protein isolates (from L. albus and L. luteus) decrease hepatic
lipids in rats [38,39], chicks [40] and hamsters [41], supporting our results. Furthermore,
lactating rats fed with lupin whole protein (from L. angustifolius) show lower concentrations
of hTC [42]. Wistar albino rats treated with LPHs (from L. albus) show less concentration of
hTG in comparison to the Ctrl group [43]. Also, an octapeptide isolated from L. angustifolius,
reduced hTG, and hTC in HFD-fed mice [44]. Despite the hepatic lipid-lowering effect
of lupin has been demonstrated, none of the previous studies have evaluated neither the
effect of LPHs from L. angustifolius nor the combined effects in the three most critical stages
of MAFLD (fat accumulation, oxidative stress and inflammation) in mice fed with WD (a
nutrition model more similar to that followed by a large part of the population in developed
countries). In accordance with these results, we have recently demonstrated the plasmatic-
cholesterol lowering effect of LPHs in ApoE−/− mice (Santos et al., under review).
In order to analyse the underlying mechanisms of the LPHs effect on the liver fat
accumulation, the mRNA expression of key genes involved in the liver lipid metabolism
was quantified. We observed a significant reduction in the CD36 hepatic gene expression
in LPHs-treated mice. The transmembrane glycoprotein CD36 plays a fundamental role in
the steatosis process providing the hepatic long-chain fatty acids uptake [45]. Thus, CD36
contributes to the hepatic fat accumulation and subsequent metabolic dysfunctions [46–48].
Previous studies have demonstrated the pathogenic role of CD36 in rodents fed with
HFD [49] and a significant upregulation of CD36 associated with an increased steatosis
in patients with NASH [13]. To the best of our knowledge, there are no previous studies
showing a reduction of hepatic CD36 expression caused by a vegetable hydrolysate.
In this regard, we suggest that the reduced levels of hTG and hepatic steatosis observed
in LPHs-treated mice could be caused by a lower fatty acids uptake, which is induced
by the downregulation of hepatic CD36. In accordance, correlation analyses showed a
significant strong positive correlation between CD36 expression and hTG levels.
Furthermore, the LDL-R expression was reduced in LPHs-treated mice. Previous
reports have suggested that LDL-R expression is increased in the liver of HFD-fed mice
as a compensatory response for the hepatic clearance of circulating LDL-cholesterol [50].
The reduction in the LDL-R expression observed in LPHs-treated mice may be related to
the presence of lower levels of liver cholesterol. This connection is in line with the positive
correlation detected between LDL-R and hepatic cholesterol levels.
We also observed an upregulation in the hepatic gene expression of AdipoR2, which
facilitates the uptake of adiponectin into the liver, in LPHs-treated mice. The overexpression
of hepatic AdipoR2 in C57BL/6 mice improves MAFLD in all stages whereas the inhibition
of AdipoR2 aggravated the disease [51]. Furthermore, NASH patients present lower levels
of hepatic adiponectin and AdipoR2 than healthy subjects [52]. Therefore, we suggest that
the overexpression of hepatic AdipoR2 is, at least partly, responsible for the hepatic lipid-
lowering effect observed in LPHs-treated mice. On the other hand, no significant differences
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in FASN gene expression were observed between groups. Therefore, we suggest that the
lower fat content in the liver of LPHs-treated mice is not due to a reduction of de novo
synthesis of triglycerides. According to the “multiple-hit” hypothesis, oxidative stress plays
a fundamental role in the pathogenesis and development of MAFLD [8]. ROS generated as a
consequence of hepatic fat accumulation cause lipid peroxidation and cytokine production,
promoting the progression of simple steatosis to NASH [53]. In addition, ROS can affect
the activity of several enzymes involved in lipid metabolism (β-oxidation and lipogenesis),
perpetuating the liver injury. In this regard, clinical evidences have demonstrated the
beneficial action of antioxidants in lipid metabolism dysfunction such as MAFLD. Both
classical antioxidants (vitamins C and E) and other natural dietary antioxidants such
as coffee components or flavonoids (hesperetin and derivates) have been described as
potential therapies in MAFLD [54,55]. MAFLD patients have high levels of ROS and lipid
peroxidation products, as well as decreased activity of the main antioxidant enzymes,
compared to healthy subjects [56,57]. Furthermore, studies in humans and animals have
shown a strong association between oxidative stress and the severity of MAFLD [58,59]. In
this study, mice treated with LPHs presented higher SOD, GPx, and GR activities, and lower
hepatic levels of lipid peroxidation products (MDA, and 4-HNE). These observations are of
special interest given that the activity of main antioxidant enzymes decreases as the disease
worsens [56,59]. Accordingly, we observed an increase in hepatic levels of FRAP in LPHs-
treated mice. FRAP is a widely used assay to measure the “general antioxidant power”,
based on the ability of a sample to reduce iron [60]. Previous studies have demonstrated
that FRAP is decreased in steatosis patients compared to healthy patients. In fact, FRAP
levels decline as the disease progresses to NASH [56]. To the best of our knowledge, this is
the first time that LPHs have been shown to improve liver antioxidant status. Thus, LPHs,
in addition to reducing hepatic lipids, could ameliorate the MAFLD progression to NASH,
through reducing oxidative stress. The inverse correlations observed between FRAP and
levels of hTG and lipidic peroxidation products support the close association between fat
accumulation and an increased oxidative stress.
Besides oxidative stress, inflammation plays an important role in the transition from
liver steatosis to NASH. Increased levels of hepatic lipids and the subsequent oxidative
stress lead to pro-inflammatory cytokines production that exacerbates liver injury [8]. Some
studies have shown that patients with MAFLD present elevated concentrations of IL-1β,
IL-6, and TNF [61–63] and low concentrations of IL-10 [64]. Moreover, TNF and IL-10 levels
have been shown to correlate with the disease stage [64,65]. In fact, IL-10−/− mice fed
with an HFD present more hTG content in comparison to the wild type group [66], while
IFNα receptor 1 or TNFα receptor 1 knockouts mice fed with hyperlipidemic diets show an
attenuated hepatic steatosis [67,68]. Also, the inhibition of IL-1β in hypercholesterolemic
mice inhibited the progression of simple steatosis to NASH and liver fibrosis [69]. In the
present study, we found that LPHs improve the hepatic anti-inflammatory environment
through increasing hepatic IL-10/TNF, IL-10/IL-1β, and IL-10/IFN-γ ratios. Other protein
hydrolysates from casein or potato have shown anti-inflammatory effects in the liver [70,71].
Furthermore, a synthetic peptide based on L. angustifolius (GPETAFLR) has been shown to
possess anti-inflammatory effects in the liver of high-fat diet induced obese mice [44]. In
this study, we demonstrated for the first time the hepatic anti-inflammatory role of LPHs in
ApoE−/− mice fed a WD, a preclinical model of MAFLD. The strong correlation observed
between FRAP and IL10/TNF ratio in LPHs-treated mice re-enforces the interplay between
the oxidative stress and inflammation in the context of fatty liver disease.
5. Conclusions
This study is the first to report the beneficial pleiotropic actions of LPHs on key steps of
MAFLD pathophysiology, including abdominal adiposity and hepatic steatosis, oxidative
stress and inflammation. Therefore, these results support the development of nutritional
strategies based on LPHs to prevent MAFLD.
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